Review
The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer
Published on: 23 October 2017
Featured series: Recent development in cancer immunotherapy
Due to recent technological and scientific advancements, the past few years have seen dramatic breakthroughs in the burgeoning field of immunotherapy. These and future advances in immunotherapy have the potential to transform cancer treatment and the lives of patients. This thematic series, published in the Journal of Hematology & Oncology, covers some of the recent advances in cancer immunotherapy.
Articles
-
-
Rapid communication
Clinical trials of CAR-T cells in China
Published on: 23 October 2017
-
Review
-
Review
The role of B cell antigen receptors in mantle cell lymphoma
Published on: 17 October 2017
-
Research
An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia
Published on: 6 October 2017
-
Review
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options
Published on: 22 March 2011
-
Review
The effects of β-glucan on human immune and cancer cells
Published on: 10 June 2009
-
Review
Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers
Published on: 25 February 2013
-
Review
Ibrutinib and novel BTK inhibitors in clinical development
Published on: 19 August 2013
-
Review
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Published on: 30 September 2013
Experimental Hematology & Oncology
Submit your research to our companion journal, Experimental Hematology & Oncology
Aims and scope
Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology.
Upcoming conference
New York Oncology Forum by the Chinese American Hematologist and Oncologist Network
November 18–19, 2017
Sheraton LaGuardia East Hotel
Editor's quote
"Journal of Hematology & Oncology provides a forum for top-quality research and is a leading title in hematology and oncology, with an Impact Factor ranked in Q1 in both categories. The journal also publishes reviews and research highlights from leading experts in the field. Research is shared with fast turnaround times in an open access format among laboratory scientists, physician scientists, hematologists and oncologists."
Prof Delong Liu, Editor-in-Chief, Journal of Hematology & Oncology
Research highlights
Journal of Hematology & Oncology is now publishing Research Highlights, commentaries on recently published work that place the new research in the context of the current literature.
Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
Janice Lu
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Jingjing Wu, Jiaping Fu, Mingzhi Zhang, Delong Liu
Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
Gaurav Goel, Weijing Sun
Advertisement
